Additionally, Xiao et al. reported a statistically significant increase in overall survival in BC-affected BRCA1 and BRCA2 carriers combined following RRSO (pooled HR 0.33, 95%CI 0.28–0.38), and Eleje et al. showed increased BCSM in BRCA1 and BRCA2 carriers combined following RRSO (pooled HR 0.58, 95%CI 0.39–0.88). The gene discussed is BRCA2; the disease is breast cancer.